See more : Crest Ventures Limited (CREST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Jupiter Wellness, Inc. (JUPW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jupiter Wellness, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- iSun, Inc. (ISUNQ) Income Statement Analysis – Financial Results
- Trupanion, Inc. (0LH0.L) Income Statement Analysis – Financial Results
- Global Warming Solutions, Inc. (GWSO) Income Statement Analysis – Financial Results
- Charoong Thai Wire and Cable Public Company Limited (CTW.BK) Income Statement Analysis – Financial Results
- CleanTech Lithium Plc (CTL.L) Income Statement Analysis – Financial Results
Jupiter Wellness, Inc. (JUPW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jupiterwellness.com
About Jupiter Wellness, Inc.
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 6.20M | 2.88M | 1.07M | 6.46K |
| Cost of Revenue | 5.17M | 2.34M | 624.57K | 18.02K |
| Gross Profit | 1.03M | 535.49K | 441.10K | -11.57K |
| Gross Profit Ratio | 16.56% | 18.62% | 41.39% | -179.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.52M | 17.31M | 5.58M | 908.72K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.52M | 17.31M | 5.58M | 908.72K |
| Other Expenses | 1.54K | 699.70K | 0.00 | 0.00 |
| Operating Expenses | 12.52M | 17.31M | 5.58M | 908.72K |
| Cost & Expenses | 17.69M | 19.65M | 6.20M | 926.74K |
| Interest Income | 1.72K | 7.32K | 3.04K | 1.38K |
| Interest Expense | 1.29M | 1.74M | 116.80K | 6.56K |
| Depreciation & Amortization | 520.81K | 187.92K | 161.37K | 171.86K |
| EBITDA | -10.97M | -16.58M | -4.97M | -918.91K |
| EBITDA Ratio | -176.99% | -576.30% | -466.44% | -14,235.55% |
| Operating Income | -11.49M | -16.76M | -5.13M | -918.91K |
| Operating Income Ratio | -185.39% | -582.83% | -481.59% | -14,235.55% |
| Total Other Income/Expenses | -3.73M | -5.71M | -1.15M | -5.18K |
| Income Before Tax | -15.22M | -28.10M | -6.29M | -925.46K |
| Income Before Tax Ratio | -245.66% | -976.97% | -590.17% | -14,337.13% |
| Income Tax Expense | 2.45M | 1.74M | 116.80K | 6.56K |
| Net Income | -17.67M | -29.84M | -6.41M | -932.02K |
| Net Income Ratio | -285.17% | -1,037.33% | -601.13% | -14,438.71% |
| EPS | -0.80 | -1.80 | -0.87 | -0.12 |
| EPS Diluted | -0.80 | -1.80 | -0.87 | -0.12 |
| Weighted Avg Shares Out | 22.11M | 16.60M | 7.33M | 7.83M |
| Weighted Avg Shares Out (Dil) | 22.11M | 16.60M | 7.33M | 7.83M |
Aegis Capital Corp. acted as Sole Bookrunner on a $32.5 Million Follow-On Offering of Common Stock and Warrants for Jupiter Wellness, Inc. (NASDAQ:JUPW).
Jupiter Wellness Closes $32.5 Million Underwritten Public Offering of Common Stock and Warrants
JUPW Stock Fell Over 20% Pre-Market: Why It Happened
Jupiter Wellness Prices $32.5 Million Underwritten Public Offering of Common Stock and Warrants
Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia
Jupiter Wellness Stock Increases Over 9%: Why It Happened
Jupiter Wellness Licenses Photocil(TM), a Novel Topical Treatment of Psoriasis, Vitiligo, Pruritis and Atopic Dermatitis
Results of Clinical Study Showing That JW 100 Significantly Reduces ISGA Score in Atopic Dermatitis (AD) Published
JUPW Stock Price Increases Over 15% Pre-Market: Why It Happened
Jupiter Wellness Licenses Patents for the Treatment of Contact Dermatitis
Source: https://incomestatements.info
Category: Stock Reports